Moleculin Biotech Highlights Strong Annamycin Phase 2 AML Data & 2026 Phase 3 Catalysts
MBRX sits 29% above its 52-week low of $3.13.
Summary
Moleculin Biotech presented an investor update detailing promising Phase 2 results for Annamycin in relapsed/refractory AML, outlining the Phase 3 MIRACLE trial with key data readouts expected in 2026, and emphasizing its non-cardiotoxic profile.
Key Events · Product Development and Regulatory · MBRX
-
Annamycin Phase 2 AML Efficacy
The company reported a 50% complete remission rate and 60% composite complete remission rate in relapsed/refractory AML, claiming over double the efficacy of current second-line therapies.
-
Phase 3 MIRACLE Trial Progress
The ongoing Phase 3 trial for Annamycin in AML has 60% of the first 45 subjects enrolled, with two unblinded data readouts expected in 2026.
-
Non-Cardiotoxic Profile
Annamycin is highlighted for its unique non-cardiotoxic profile, a significant differentiator for an anthracycline, supported by independent expert review.
-
Upcoming Milestones
Multiple clinical milestones are anticipated for 2026, including further data readouts for Annamycin in AML and progress in other pipeline programs.
Analysis · MBRX · Life Sciences
This 8-K filing, attaching an investor presentation, provides a comprehensive update on Moleculin Biotech's clinical pipeline, particularly its lead asset, Annamycin. The presentation highlights compelling Phase 2 efficacy data for Annamycin in relapsed/refractory Acute Myeloid Leukemia (AML), claiming a complete remission rate more than double that of leading second-line treatments. The ongoing Phase 3 MIRACLE trial, designed with FDA guidance, is a critical next step, with two unblinded data readouts anticipated in 2026. The drug's non-cardiotoxic profile is a significant differentiator in the anthracycline class. While the company acknowledges the need for additional financing to support its clinical programs, the near-term catalysts from the MIRACLE trial and other pipeline developments could be transformative for this nano-cap biotech. Investors should closely monitor the upcoming data readouts and financing activities.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.4% of the 1217 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $4.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $3.13 to $91.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.